CD37

Summary

CD37 (CD37 molecule, HGNC:1666) is a protein-coding gene on chromosome 19q13.33, encoding Leukocyte antigen CD37 (P11049). Structural component of specialized membrane microdomains known as tetraspanin-enriched microdomains (TERMs), which act as platforms for receptor clustering and signaling.

The protein encoded by this gene is a member of the transmembrane 4 superfamily, also known as the tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. This encoded protein is a cell surface glycoprotein that is known to complex with integrins and other transmembrane 4 superfamily proteins. It may play a role in T-cell-B-cell interactions. Alternate splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 951 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 45 total
• Druggable target: yes
• MANE Select transcript: NM_001774

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1666
Approved symbol	CD37
Name	CD37 molecule
Location	19q13.33
Locus type	gene with protein product
Status	Approved
Aliases	TSPAN26
Ensembl gene	ENSG00000104894
Ensembl biotype	protein_coding
OMIM	151523
Entrez	951

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 11 protein_coding, 3 retained_intron, 3 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000323906, ENST00000391859, ENST00000426897, ENST00000535669, ENST00000593512, ENST00000594743, ENST00000595660, ENST00000595725, ENST00000596426, ENST00000597033, ENST00000597602, ENST00000597852, ENST00000598095, ENST00000598134, ENST00000600121, ENST00000890245, ENST00000890246, ENST00000890247, ENST00000944451

RefSeq mRNA: 2 — MANE Select: NM_001774 NM_001040031, NM_001774

CCDS: CCDS12760, CCDS46139

Canonical transcript exons

ENST00000323906 — 8 exons

Exon	Start	End
ENSE00003055340	49340251	49340606
ENSE00003483623	49335714	49335786
ENSE00003495833	49339330	49339413
ENSE00003509640	49337147	49337221
ENSE00003610751	49336909	49337033
ENSE00003625640	49337925	49338029
ENSE00003633467	49338700	49338936
ENSE00003848887	49335406	49335609

Expression profiles

Bgee: expression breadth ubiquitous, 194 present calls, max score 99.59.

FANTOM5 (CAGE): breadth broad, TPM avg 130.0043 / max 7768.1553, expressed in 592 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
176958	128.6442	590
176962	1.2185	253
176963	0.1416	71

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	99.59	gold quality
monocyte	CL:0000576	99.28	gold quality
leukocyte	CL:0000738	99.25	gold quality
mononuclear cell	CL:0000842	99.22	gold quality
spleen	UBERON:0002106	98.74	gold quality
vermiform appendix	UBERON:0001154	97.90	gold quality
bone marrow cell	CL:0002092	97.09	gold quality
blood	UBERON:0000178	97.09	gold quality
lymph node	UBERON:0000029	97.08	gold quality
bone marrow	UBERON:0002371	96.64	gold quality
right lung	UBERON:0002167	95.10	gold quality
gall bladder	UBERON:0002110	94.35	gold quality
upper lobe of left lung	UBERON:0008952	94.34	gold quality
upper lobe of lung	UBERON:0008948	93.16	gold quality
small intestine Peyer’s patch	UBERON:0003454	92.79	gold quality
caecum	UBERON:0001153	91.75	gold quality
colonic epithelium	UBERON:0000397	90.45	gold quality
sural nerve	UBERON:0015488	90.37	gold quality
trabecular bone tissue	UBERON:0002483	90.06	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	89.98	gold quality
ileal mucosa	UBERON:0000331	89.87	gold quality
rectum	UBERON:0001052	89.38	gold quality
right coronary artery	UBERON:0001625	89.14	gold quality
small intestine	UBERON:0002108	88.92	gold quality
mucosa of transverse colon	UBERON:0004991	88.16	gold quality
omental fat pad	UBERON:0010414	87.60	gold quality
peritoneum	UBERON:0002358	87.51	gold quality
spinal cord	UBERON:0002240	86.46	gold quality
adipose tissue of abdominal region	UBERON:0007808	86.39	gold quality
thymus	UBERON:0002370	85.43	gold quality

Single-cell (SCXA)

Detected in 48 experiment(s), a significant marker in 44.

Experiment	Marker?	Max mean expression
E-MTAB-8911	yes	3553.01
E-HCAD-4	yes	3499.85
E-CURD-55	yes	3470.62
E-GEOD-149689	yes	2738.81
E-CURD-122	yes	2582.69
E-MTAB-8207	yes	2380.46
E-MTAB-10042	yes	2196.29
E-MTAB-7407	yes	2154.20
E-MTAB-10553	yes	1956.65
E-MTAB-9906	yes	1880.40
E-HCAD-24	yes	1867.30
E-HCAD-1	yes	1836.62
E-MTAB-8884	yes	1760.38
E-CURD-88	yes	1748.77
E-MTAB-8530	yes	1697.48

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

19 targeting CD37, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-6793-5P	99.97	65.95	758
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-1909-3P	99.03	66.56	1662
HSA-MIR-4700-5P	98.63	67.43	1915
HSA-MIR-4450	98.26	68.35	725
HSA-MIR-1233-5P	98.19	66.71	1201
HSA-MIR-6778-5P	98.19	66.59	1239
HSA-MIR-1262	98.17	66.52	757
HSA-MIR-4701-3P	98.17	66.25	788
HSA-MIR-6736-5P	98.17	66.43	760
HSA-MIR-4483	98.09	64.12	1642
HSA-MIR-8089	97.74	66.21	1698
HSA-MIR-4667-5P	97.61	66.67	1683
HSA-MIR-1293	96.16	64.69	916

Literature-anchored findings (GeneRIF, showing 17)

• CD37 cross-linking on human T cells transduces signals that lead to complete inhibition of CD3-induced T cell proliferation. (PMID:14978098)
• CD37 is important for dectin-1 stabilization in APC membranes and controls dectin-1-mediated IL-6 production. (PMID:17182550)
• provide strong justification for CD37 as a therapeutic target and introduce small modular immunopharmaceuticals as a novel class of targeted therapies for B-cell malignancies (PMID:17440052)
• In the absence of both CD37 and Tssc6, immune function is further altered when compared with CD37- or Tssc6-deficient transgenic mice, demonstrating a complementary role for these two molecules in cellular immunity. (PMID:20709950)
• Identify two tyrosine residues in tetraspanin CD37 directly mediating transduction of survival and apoptotic signals. (PMID:22624718)
• Data indicate that enhanced antibody-dependent cell cytotoxicity (ADCC) is observed against chronic lymphocytic leukemia cells and is sustained at concentrations of SMIP-016(GV) as low at 5E(-6) microg/mL on cells expressing minimal CD37 antigen. (PMID:23883821)
• The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. (PMID:24445867)
• Data indicate that cell differentiation antigen 37 (CD37) is well expressed and a potential drug target in acute myeloid leukemia (AML). (PMID:25934707)
• CD37 is a critical determinant of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone outcome in diffuse large B-cell lymphoma. (PMID:27760757)
• CD37 is highly expressed in human lymphoma. (PMID:30089630)
• tetraspanin CD37 controls CLEC-2 membrane organization and provides new molecular insights into the mechanisms underlying CLEC-2-dependent dendritic cell migration. (PMID:30185523)
• Low CD37 expression is associated with brain metastasis in lung cancer. (PMID:30854931)
• The anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. (PMID:31089249)
• From a cohort of 137 primary diffuse large B-cell lymphoma (DLBCL) samples. CD37 mutations were exclusively identified in immune-privileged site-associated DLBCL (IP-DLBCL) cases but absent in non-IP-DLBCL cases. Modeling and functional analysis of CD37 missense mutations revealed loss of function by impaired CD37 protein expression at the plasma membrane of human lymphoma B cells. (PMID:31366619)
• CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia. (PMID:32400873)
• CD37 expression in follicular lymphoma. (PMID:35171311)
• CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies. (PMID:38846084)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cd37	ENSDARG00000075515
mus_musculus	Cd37	ENSMUSG00000030798
rattus_norvegicus	Cd37	ENSRNOG00000020699

Paralogs (32): TSPAN6 (ENSG00000000003), CD9 (ENSG00000010278), TSPAN9 (ENSG00000011105), TSPAN17 (ENSG00000048140), TSPAN32 (ENSG00000064201), CD82 (ENSG00000085117), TSPAN15 (ENSG00000099282), UPK1A (ENSG00000105668), TSPAN12 (ENSG00000106025), TSPAN13 (ENSG00000106537), TSPAN14 (ENSG00000108219), CD81 (ENSG00000110651), TSPAN11 (ENSG00000110900), PRPH2 (ENSG00000112619), UPK1B (ENSG00000114638), TSPAN1 (ENSG00000117472), TSPAN8 (ENSG00000127324), TSPAN16 (ENSG00000130167), TSPAN2 (ENSG00000134198), CD63 (ENSG00000135404), TSPAN31 (ENSG00000135452), TSPAN3 (ENSG00000140391), CD53 (ENSG00000143119), ROM1 (ENSG00000149489), TSPAN7 (ENSG00000156298), TSPAN18 (ENSG00000157570), TSPAN33 (ENSG00000158457), TSPAN5 (ENSG00000168785), CD151 (ENSG00000177697), TSPAN10 (ENSG00000182612), TSPAN4 (ENSG00000214063), TSPAN19 (ENSG00000231738)

Protein

Protein identifiers

Leukocyte antigen CD37 — P11049 (reviewed: P11049)

Alternative names: Tetraspanin-26

All UniProt accessions (7): P11049, B7ZAN3, M0QZ33, M0QZP6, M0R083, M0R1J1, Q96LM7

UniProt curated annotations — full annotation on UniProt →

Function. Structural component of specialized membrane microdomains known as tetraspanin-enriched microdomains (TERMs), which act as platforms for receptor clustering and signaling. Participates thereby in diverse biological functions such as cell signal transduction, adhesion, migration and protein trafficking. Upon ligand binding, two signaling pathways are activated, one acting through phosphorylation by LYN leading to cell death or a survival pathway with activation of GSK3B. Plays an essential role essential for clustering of integrin ITGA4/ITGB1 and promotes its mobility in the plasma membrane of B-cells. In turn, participates in ITGA4/ITGB1 integrin-mediated antiapoptotic signaling through AKT. Also plays a role in the migration of dendritic cells and neutrophils to draining lymph nodes, as well as in their integrin-mediated adhesion. Negatively regulates IL-6 responses through direct interaction with SOCS3 thereby preventing constitutive IL-6 signaling. Alternatively, inhibition of IL-6 signaling can also occur via interaction and stabilization of DECTIN1/CLEC7A at the cell membrane to inhibit its ability to promote the production of IL-6.

Subunit / interactions. Interacts with SCIMP. Interacts with SOCS3. Interacts with DECTIN1/CLEC7A.

Subcellular location. Cell membrane.

Tissue specificity. B-lymphocytes. Antigen presenting cells.

Post-translational modifications. Tyrosine phosphorylated; leading to activation of downstream signaling pathways.

Similarity. Belongs to the tetraspanin (TM4SF) family.

Isoforms (3)

UniProt ID	Names	Canonical?
P11049-1	1	yes
P11049-2	2
P11049-3	3

RefSeq proteins (2): NP_001035120, NP_001765* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000301	Tetraspanin_animals	Family
IPR008952	Tetraspanin_EC2_sf	Homologous_superfamily
IPR018499	Tetraspanin/Peripherin	Family
IPR018503	Tetraspanin_CS	Conserved_site

Pfam: PF00335

UniProt features (17 total): topological domain 5, transmembrane region 4, glycosylation site 3, splice variant 2, mutagenesis site 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P11049-F1	83.31	0.53

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (3): 170, 183, 188

Mutagenesis-validated functional residues (2):

Position	Phenotype
13	complete loss of surface expression.
274	no loss of surface expression but significant increase of cd37-mediated cell death.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 262 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, WALLACE_PROSTATE_CANCER_RACE_UP, MCLACHLAN_DENTAL_CARIES_UP, GOBP_REGULATION_OF_DEFENSE_RESPONSE_TO_VIRUS, MODULE_45, MODULE_64, TGACCTY_ERR1_Q2, GGGTGGRR_PAX4_03, HAHTOLA_MYCOSIS_FUNGOIDES_DN, MODULE_118, GOBP_REGULATION_OF_IMMUNOGLOBULIN_PRODUCTION, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_MYELOID_LEUKOCYTE_ACTIVATION

GO Biological Process (7): positive regulation of immunoglobulin production (GO:0002639), regulation of humoral immune response (GO:0002920), negative regulation of myeloid dendritic cell activation (GO:0030886), T cell proliferation (GO:0042098), negative regulation of T cell proliferation (GO:0042130), defense response to protozoan (GO:0042832), regulation of defense response to virus (GO:0050688)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): immunological synapse (GO:0001772), plasma membrane (GO:0005886), membrane (GO:0016020), extracellular exosome (GO:0070062)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
immunoglobulin production	1
regulation of immunoglobulin production	1
positive regulation of production of molecular mediator of immune response	1
humoral immune response	1
regulation of immune response	1
myeloid dendritic cell activation	1
negative regulation of leukocyte activation	1
regulation of myeloid dendritic cell activation	1
T cell activation	1
lymphocyte proliferation	1
T cell proliferation	1
regulation of T cell proliferation	1
negative regulation of lymphocyte proliferation	1
negative regulation of T cell activation	1
response to protozoan	1
defense response to other organism	1
regulation of response to biotic stimulus	1
regulation of defense response	1
regulation of response to external stimulus	1
defense response to virus	1
binding	1
plasma membrane	1
membrane	1
cell periphery	1
extracellular vesicle	1

Protein interactions and networks

STRING

1300 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CD37	CLEC7A	Q9BXN2	930
CD37	CD19	P15391	865
CD37	B4E171	B4E171	829
CD37	CD82	P27701	791
CD37	CR2	P20023	774
CD37	CD9	P21926	747
CD37	CD2	P06729	727
CD37	UPK1A	O00322	725
CD37	CD81	P18582	706
CD37	UPK1B	O75841	697
CD37	TSPAN31	Q12999	688
CD37	CD63	P08962	688
CD37	TM4SF1	P30408	666
CD37	CD53	P19397	662
CD37	PIK3CG	P48736	651

IntAct

31 interactions, top by confidence:

A	B	Type	Score
CD37	LHFPL5	psi-mi:“MI:0915”(physical association)	0.560
CD37	LRRC3B	psi-mi:“MI:0915”(physical association)	0.560
CD37	CD53	psi-mi:“MI:0915”(physical association)	0.560
CD37	EMP1	psi-mi:“MI:0915”(physical association)	0.560
GJB1	CD37	psi-mi:“MI:0915”(physical association)	0.560
PTPN6	CD37	psi-mi:“MI:0915”(physical association)	0.500
LYN	CD37	psi-mi:“MI:0915”(physical association)	0.500
CD37	SYK	psi-mi:“MI:0915”(physical association)	0.500
CD37	LYN	psi-mi:“MI:0914”(association)	0.500
SYK	CD37	psi-mi:“MI:0915”(physical association)	0.500
CD37	PTPN6	psi-mi:“MI:0915”(physical association)	0.500
CD37	SCIMP	psi-mi:“MI:0914”(association)	0.460
SCIMP	CD37	psi-mi:“MI:0914”(association)	0.460
PIK3CD	CD37	psi-mi:“MI:0915”(physical association)	0.400
CD37	PIK3CG	psi-mi:“MI:0915”(physical association)	0.400
CD37	AGTR1	psi-mi:“MI:0915”(physical association)	0.370
CD37	CD53	psi-mi:“MI:0915”(physical association)	0.000
CD37	EMP1	psi-mi:“MI:0915”(physical association)	0.000
CD37	GJB1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (9): EMP1 (Two-hybrid), CD53 (Two-hybrid), GJB1 (Two-hybrid), LRRC3B (Two-hybrid), LHFPL5 (Two-hybrid), CD37 (Two-hybrid), CD37 (Affinity Capture-RNA), CD37 (Affinity Capture-RNA), CD37 (Affinity Capture-RNA)

ESM2 similar proteins: A0A8M2B5N2, A0A8V0ZLT4, A1L157, O00322, O60637, O75841, P11049, P19075, P21926, P30409, P30413, P30932, P31053, P38572, P38573, P40239, P40240, P40241, Q0D289, Q2KHY8, Q2MJQ7, Q3SZR9, Q4R4Z3, Q4R7W6, Q566D0, Q568Y5, Q58CY8, Q5RDV7, Q5RE11, Q5RH71, Q61470, Q6AYR9, Q6GQF5, Q6P0C6, Q6ZUX7, Q80WR1, Q8WMQ3, Q91Y55, Q925N4, Q96FX8

Diamond homologs: A0A8M2B5N2, A0A8V0ZLT4, B0BM39, B3VSC2, B5X3I6, O14817, O60635, O75954, O97703, P11049, P60033, P60034, Q06AA5, Q11098, Q26499, Q3T0S3, Q4R7W6, Q4V8E0, Q58CY8, Q5RAP3, Q5RC27, Q61470, Q6AYR9, Q6DCQ3, Q6GMK6, Q80WR1, Q8BJU2, Q922J6, Q96SJ8, Q99J59, Q9DCK3, O60636, P19397, P24485, P30932, P35762, P40240, P62079, P62080, Q17QJ5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

45 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	35
Likely benign	3
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1712 predictions. Top by Δscore:

Variant	Effect	Δscore
19:49335610:G:GG	donor_gain	1.0000
19:49335770:C:G	donor_gain	1.0000
19:49336905:CCA:C	acceptor_loss	1.0000
19:49336906:CAG:C	acceptor_loss	1.0000
19:49336907:A:AG	acceptor_gain	1.0000
19:49336907:AGGCT:A	acceptor_loss	1.0000
19:49336908:G:GG	acceptor_gain	1.0000
19:49336908:GGC:G	acceptor_gain	1.0000
19:49336908:GGCTT:G	acceptor_gain	1.0000
19:49337029:GCCTG:G	donor_gain	1.0000
19:49337030:CCTGG:C	donor_loss	1.0000
19:49337031:CTGG:C	donor_loss	1.0000
19:49337033:GGTG:G	donor_loss	1.0000
19:49337034:G:GG	donor_gain	1.0000
19:49337034:GTGA:G	donor_loss	1.0000
19:49337035:T:G	donor_loss	1.0000
19:49337144:CAG:C	acceptor_loss	1.0000
19:49337145:A:AG	acceptor_gain	1.0000
19:49337146:G:GA	acceptor_gain	1.0000
19:49337146:GT:G	acceptor_gain	1.0000
19:49337146:GTAT:G	acceptor_gain	1.0000
19:49337220:AGGT:A	donor_loss	1.0000
19:49337221:GGTG:G	donor_loss	1.0000
19:49337222:GTG:G	donor_loss	1.0000
19:49337920:CTCAG:C	acceptor_loss	1.0000
19:49337923:AGC:A	acceptor_loss	1.0000
19:49337923:AGCT:A	acceptor_gain	1.0000
19:49337924:GCT:G	acceptor_gain	1.0000
19:49337924:GCTG:G	acceptor_gain	1.0000
19:49337926:T:A	acceptor_gain	1.0000

AlphaMissense

1827 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:49338735:G:C	W161C	0.994
19:49338735:G:T	W161C	0.994
19:49335723:A:C	S27R	0.991
19:49335725:C:A	S27R	0.991
19:49335725:C:G	S27R	0.991
19:49338712:G:T	G154C	0.989
19:49335720:G:C	G26R	0.988
19:49336960:G:A	G65E	0.988
19:49335597:C:A	N19K	0.987
19:49335597:C:G	N19K	0.987
19:49336959:G:A	G65R	0.987
19:49336959:G:C	G65R	0.987
19:49338709:T:A	C153S	0.986
19:49338710:G:A	C153Y	0.986
19:49338710:G:C	C153S	0.986
19:49338706:T:A	C152S	0.985
19:49338707:G:C	C152S	0.985
19:49339333:T:A	C230S	0.983
19:49339334:G:C	C230S	0.983
19:49336990:G:A	G75D	0.982
19:49339390:T:C	C249R	0.982
19:49335721:G:A	G26D	0.981
19:49335735:T:C	C31R	0.981
19:49338009:T:A	W143R	0.981
19:49338009:T:C	W143R	0.981
19:49338793:T:A	C181S	0.981
19:49338794:G:C	C181S	0.981
19:49336989:G:C	G75R	0.980
19:49336981:C:A	A72D	0.979
19:49338011:G:C	W143C	0.979

dbSNP variants (sampled 300 via entrez): RS1000234674 (19:49335668 A>C,G), RS1000800657 (19:49335347 G>A,C), RS1001030324 (19:49339060 A>G), RS1001543856 (19:49334411 G>A), RS1002019172 (19:49341030 T>TA), RS1002116492 (19:49335144 C>T), RS1002162077 (19:49334752 G>A), RS1002620669 (19:49339609 G>A), RS1003028928 (19:49339744 G>A,C,T), RS1003122993 (19:49333786 T>G), RS1003624244 (19:49338312 C>T), RS1004458947 (19:49336016 G>A,C,T), RS1004873051 (19:49336271 A>G), RS1004981427 (19:49340907 G>A), RS1005470440 (19:49334674 T>A)

Disease associations

OMIM: gene MIM:151523 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3712880 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — CD molecules

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
naratuximab emtansine	Binding	9.3	pEC50
lilotomab	Binding	8.57	pKd

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Acetaminophen	decreases expression, increases expression	2
Nickel	increases expression	2
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	decreases expression	1
prothioconazole	decreases expression	1
Arsenic	decreases methylation	1
Benzo(a)pyrene	decreases methylation, increases methylation	1
Cisplatin	decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Diuron	decreases expression	1
Lead	decreases expression	1
Phthalic Acids	increases methylation	1
Testosterone	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	increases expression	1
Valproic Acid	increases methylation	1
Isotretinoin	increases expression	1
Antirheumatic Agents	decreases expression	1
Copper Sulfate	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5148893	Binding	Inhibition of C-terminal his tagged recombinant human CD37 (27 to 547 residues) expressed in HEK293 cells at 10 uM by spectrophotometer based microplate reader method relative to control	Orally Bioavailable Enzymatic Inhibitor of CD38, MK-0159, Protects against Ischemia/Reperfusion Injury in the Murine Heart. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.